184 related articles for article (PubMed ID: 29625108)
1. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
[TBL] [Abstract][Full Text] [Related]
2. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
[TBL] [Abstract][Full Text] [Related]
3. Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.
Wang G; Sai K; Gong F; Yang Q; Chen F; Lin J
Mol Med Rep; 2014 May; 9(5):1799-805. PubMed ID: 24626950
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
Tang JH; Ma ZX; Huang GH; Xu QF; Xiang Y; Li N; Sidlauskas K; Zhang EE; Lv SQ
Exp Cell Res; 2016 May; 343(2):148-158. PubMed ID: 27090014
[TBL] [Abstract][Full Text] [Related]
6. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
7. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
8. Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.
Fu Y; Zheng S; Zheng Y; Huang R; An N; Liang A; Hu C
Int J Biochem Cell Biol; 2012 May; 44(5):770-5. PubMed ID: 22309944
[TBL] [Abstract][Full Text] [Related]
9. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.
Ma D; Zhan D; Fu Y; Wei S; Lal B; Wang J; Li Y; Lopez-Bertoni H; Yalcin F; Dzaye O; Eberhart CG; Laterra J; Wilson MA; Ying M; Xia S
Cancer Lett; 2021 Oct; 517():35-45. PubMed ID: 34098063
[TBL] [Abstract][Full Text] [Related]
10. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Shi J; Sun B; Shi W; Zuo H; Cui D; Ni L; Chen J
Tumour Biol; 2015 Feb; 36(2):655-62. PubMed ID: 25283382
[TBL] [Abstract][Full Text] [Related]
11. IDH1-R132H Suppresses Glioblastoma Malignancy through FAT1-ROS-HIF-1α Signaling.
Li LC; Zhang M; Feng YK; Wang XJ
Neurol India; 2020; 68(5):1050-1058. PubMed ID: 33109851
[TBL] [Abstract][Full Text] [Related]
12. R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes.
Kawakami S; Ochiai K; Azakami D; Kato Y; Michishita M; Morimatsu M; Ishiguro-Oonuma T; Onozawa E; Watanabe M; Omi T
Vet Res Commun; 2018 Mar; 42(1):49-56. PubMed ID: 29285579
[TBL] [Abstract][Full Text] [Related]
13. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
14. MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations.
Cui D; Sajan P; Shi J; Shen Y; Wang K; Deng X; Zhou L; Hu P; Gao L
Oncotarget; 2017 Apr; 8(15):25345-25361. PubMed ID: 28445981
[TBL] [Abstract][Full Text] [Related]
15. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
16. DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
Zhou D; Wan Y; Xie D; Wang Y; Wei J; Yan Q; Lu P; Mo L; Xie J; Yang S; Qi X
Exp Mol Med; 2015 Sep; 47(9):e182. PubMed ID: 26337869
[TBL] [Abstract][Full Text] [Related]
17. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
[TBL] [Abstract][Full Text] [Related]
18. LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma.
Wu C; Su J; Long W; Qin C; Wang X; Xiao K; Li Y; Xiao Q; Wang J; Pan Y; Liu Q
J Cell Mol Med; 2020 Oct; 24(20):12094-12106. PubMed ID: 32916774
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
20. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Zhao S; Lin Y; Xu W; Jiang W; Zha Z; Wang P; Yu W; Li Z; Gong L; Peng Y; Ding J; Lei Q; Guan KL; Xiong Y
Science; 2009 Apr; 324(5924):261-5. PubMed ID: 19359588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]